- All sections
- A - Human necessities
- A61P - Specific therapeutic activity of chemical compounds or medicinal preparations
- A61P 5/48 - Drugs for disorders of the endocrine system of the pancreatic hormones
Patent holdings for IPC class A61P 5/48
Total number of patents in this class: 308
10-year publication summary
8
|
4
|
17
|
26
|
15
|
18
|
14
|
20
|
22
|
11
|
2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
Principal owners for this class
Owner |
All patents
|
This class
|
---|---|---|
Adocia | 144 |
9 |
Zealand Pharma A/S | 259 |
9 |
Novo Nordisk A/S | 2286 |
8 |
President and Fellows of Harvard College | 5993 |
6 |
Seraxis, Inc. | 18 |
6 |
Société des Produits Nestlé S.A. | 9296 |
5 |
DSM IP Assets B.V. | 5589 |
5 |
Inserm (institut National de La Sante et de La Recherche Medicale) | 3362 |
5 |
Boehringer Ingelheim International GmbH | 4641 |
4 |
Takeda Pharmaceutical Company Limited | 2711 |
4 |
Icahn School of Medicine at Mount Sinai | 955 |
4 |
Vertex Pharmaceuticals Incorporated | 1602 |
3 |
Camurus AB | 142 |
3 |
Shanghai Institute of Materia Medica, Chinese Academy of Sciences | 830 |
3 |
Universidade Federal do Rio de Janeiro | 59 |
3 |
University of Pittsburgh - Of the Commonwealth System of Higher Education | 3171 |
3 |
Xuanzhu Pharma Co., Ltd. | 52 |
3 |
Novartis AG | 10741 |
2 |
Amgen Inc. | 4081 |
2 |
Medtronic MiniMed, Inc. | 1804 |
2 |
Other owners | 219 |